miR-132/212 Impairs Cardiomyocytes Contractility in the Failing Heart by Suppressing SERCA2a.

miR-132/212 Impairs Cardiomyocytes Contractility in the Failing Heart by Suppressing SERCA2a.
复制标题

DOI:
10.3389/fcvm.2021.592362
复制
发表时间:
2021
影响因子:
3.6
通讯作者:
Sluijter JPG
Sluijter JPG
中科院分区:
医学3区
文献类型:
--
作者:
Lei Z;Wahlquist C;El Azzouzi H;Deddens JC;Kuster D;van Mil A;Rojas-Munoz A;Huibers MM;Mercola M;de Weger R;Van der Velden J;Xiao J;Doevendans PA;Sluijter JPG

文献摘要

参考文献

被引文献

相似文献

心脏功能受损是心力衰竭的一个标志,主要表现为由于钙处理失调导致收缩能力下降。不幸的是,导致钙处理受损的潜在机制仍不完全清楚。此前,miR-132/212 家族被确定为衰竭小鼠心脏中心脏功能的调节剂,并且药物抑制 miR-132 对于心力衰竭有益。在本研究中,我们进一步研究了 miR-132/212 在心力衰竭病理进展背景下调节心肌细胞收缩力的分子机制。我们发现在所有检查的肥厚性心力衰竭小鼠模型中 miR-132/212 表达上调。 miR-132/212 的过表达延长了分离的新生大鼠心肌细胞中的钙衰变,而从 miR-132/212 KO 小鼠中分离的心肌细胞与野生型对照相比显示出增强的收缩性。为了应对慢性压力超负荷,miR-132/212 KO 小鼠表现出心脏功能的减弱。通过结合生化方法和体外测定,我们证实 miR-132/212 通过靶向 SERCA2a 的 3' 端非翻译区来调节 SERCA2a。此外,我们还证实 PTEN 是 miR-132/212 的直接靶标,并可能参与对 miR132/212 的心脏反应。在终末期心力衰竭患者中,miR-132/212 上调并与 SERCA2a 表达减少相关。心力衰竭中 miR-132/212 的上调通过靶向 SERCA2a 损害心脏收缩功能,表明药物抑制 miR-132/212 可能是促进心力衰竭患者心功能的一种有前景的治疗方法。
Compromised cardiac function is a hallmark for heart failure, mostly appearing as decreased contractile capacity due to dysregulated calcium handling. Unfortunately, the underlying mechanism causing impaired calcium handling is still not fully understood. Previously the miR-132/212 family was identified as a regulator of cardiac function in the failing mouse heart, and pharmaceutically inhibition of miR-132 is beneficial for heart failure. In this study, we further investigated the molecular mechanisms of miR-132/212 in modulating cardiomyocyte contractility in the context of the pathological progression of heart failure. We found that upregulated miR-132/212 expressions in all examined hypertrophic heart failure mice models. The overexpression of miR-132/212 prolongs calcium decay in isolated neonatal rat cardiomyocytes, whereas cardiomyocytes isolated from miR-132/212 KO mice display enhanced contractility in comparison to wild type controls. In response to chronic pressure-overload, miR-132/212 KO mice exhibited a blunted deterioration of cardiac function. Using a combination of biochemical approaches and in vitro assays, we confirmed that miR-132/212 regulates SERCA2a by targeting the 3′-end untranslated region of SERCA2a. Additionally, we also confirmed PTEN as a direct target of miR-132/212 and potentially participates in the cardiac response to miR132/212. In end-stage heart failure patients, miR-132/212 is upregulated and correlates with reduced SERCA2a expression. The up-regulation of miR-132/212 in heart failure impairs cardiac contractile function by targeting SERCA2a, suggesting that pharmaceutical inhibition of miR-132/212 might be a promising therapeutic approach to promote cardiac function in heart failure patients.
DOI: 10.3390/ijms140611190
发表时间: 2013-05-27
影响因子: 5.6
作者:
Eskildsen TV;Jeppesen PL;Schneider M;Nossent AY;Sandberg MB;Hansen PB;Jensen CH;Hansen ML;Marcussen N;Rasmussen LM;Bie P;Andersen DC;Sheikh SP
通讯作者: Sheikh SP
DOI: 10.1042/bj20100024
发表时间: 2010-06-01
影响因子: 4.1
作者:
Remenyi, Judit;Hunter, Christopher J.;Arthur, J. Simon C.
通讯作者: Arthur, J. Simon C.
DOI: 10.1016/s0008-6363(02)00230-4
发表时间: 2002-04-01
影响因子: 10.8
作者:
Chu, GX;Carr, AN;Kranias, EG
通讯作者: Kranias, EG
DOI: 10.1161/circulationaha.111.022889
发表时间: 2011-07-19
期刊: Circulation
影响因子: 37.8
作者:
Jessup M;Greenberg B;Mancini D;Cappola T;Pauly DF;Jaski B;Yaroshinsky A;Zsebo KM;Dittrich H;Hajjar RJ;Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators
通讯作者: Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators
DOI: 10.1016/j.vascn.2012.08.167
发表时间: 2012-11
影响因子: 1.9
作者:
Cerignoli F;Charlot D;Whittaker R;Ingermanson R;Gehalot P;Savchenko A;Gallacher DJ;Towart R;Price JH;McDonough PM;Mercola M
通讯作者: Mercola M